Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the Recombinant human anti-PD-1 Monoclonal Antibody for Subjects with Advanced Solid Tumors

Trial Profile

A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the Recombinant human anti-PD-1 Monoclonal Antibody for Subjects with Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2018

At a glance

  • Drugs GLS 010 (Primary)
  • Indications Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Guangzhou Gloria Biosciences
  • Most Recent Events

    • 22 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top